Ping An Biomedical Co., Ltd. Announces Receipt of Nasdaq Minimum Bid Price Deficiency Letter

Core Viewpoint - Ping An Biomedical Co., Ltd. has received a deficiency letter from Nasdaq regarding its minimum bid price requirement, indicating potential risks to its continued listing status [2][3]. Group 1: Compliance and Listing Status - The company was notified by Nasdaq that it no longer meets the minimum bid price requirement of $1 per share based on its closing bid price from October 10, 2025, to November 20, 2025 [2]. - Nasdaq has granted the company a compliance period of 180 calendar days, until May 25, 2026, to regain compliance with the listing requirement [3]. - If the company fails to regain compliance within the initial compliance period, it may be eligible for an additional 180 days, provided it meets other listing standards and notifies Nasdaq of its intention to cure the deficiency [3]. Group 2: Company's Response and Future Plans - The company is currently evaluating options to regain compliance and is committed to making reasonable efforts to meet Nasdaq's continued listing requirements [4]. - There is no assurance that the company will successfully regain compliance with the minimum bid price rule or other Nasdaq requirements [4]. Group 3: Company Overview - Ping An Biomedical Co., Ltd. is a one-stop supply chain management service provider in the apparel industry and focuses on innovative solutions in healthcare and biomedical technology [5].